Assessing cardiovascular risk profile of immunosuppressive agents

Transplantation

Volumn 72, Issue 12 SUPPL., 2001, Pages

  Jardine, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035677622     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Long-term survival in renal transplant recipients with graft function
2. Ischemic heart disease - Major cause of death and graft loss after renal transplantation in Scandinavia
3. Chronic renal allograft failure: Clinical overview. The Leuven collaborative group for transplantation
4. Alloimmune-independent risk factors for chronic renal allograft dysfunction
5. Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion
6. Report on management of renal failure in Europe, XXII, 1991
7. Clinical epidemiology of cardiovascular disease in chronic renal disease
8. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
9. Explained and unexplained ischemic heart disease after renal transplantation
10. Cardiovascular disease after renal transplantation
11. Risk factors for accelerated atherosclerosis in renal transplant recipients
12. Cigarette smoking in renal transplant recipients
13. Outcome and risk factors for left ventricular disorders in chronic uraemia
14. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
15. Pretransplant management of end-stage renal disease patients to minimize posttransplant risk
16. Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation
17. Management strategies for post-transplant hypertension
18. Long-term results of 1047 cadaveric kidney transplantations with special emphasis on initial graft function and rejection
19. Time dependency of factors affecting renal allograft survival
20. Renal transplantation in Helsinki: Influence on long-term survival of early posttransplant factors
21. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection
22. Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients
23. Delayed graft function: Risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation
24. Earley graft function and patient survival following cadaveric renal transplantation
25. Factors influencing long-term primary cadaveric kidney transplantation - Importance of functional renal mass versus avoidance of acute rejections. The Toronto Hospital Experience 1985-1997
26. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients
27. Immunologic factors: The major risk for decreased long-term renal allograft survival
28. The impact of an acute rejection episode on long-term renal allograft survival (t1/2)
29. Acute rejection is a major risk factor for chronic rejection
30. Clinical predictors of chronic renal allograft rejection
31. Cardiovascular disease after renal transplantation
32. Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes
33. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
34. Improved graft survival after renal transplantation in the United States, 1988 to 1996
35. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
36. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
37. Sirolimus improves renal function without increasing acute rejection after cyclosporine elimination in renal transplant patients
38. Renal function improvement after switch from calcineurin-dependent drugs to sirolimus in renal transplant recipients with chronic graft nephropathy
39. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients
40. Association of chronic kidney graft failure with recipient blood pressure
41. Graft and patient survival following renal transplantation: New targets for blood pressure control
42. Mechanisms of development of heart failure in the hypertensive patient
43. Hypertension and sudden cardiac death
44. Cardiac and vascular abnormalities in renal transplant patients: Differential effects of cyclosporin and azathioprine
45. Impact and management of hyperlipidemia post-transplantation
46. Is nonnephrotoxic immunosuppression a possibility?
47. Vascular and cellular mechanisms of chronic renal allograft dysfunction
48. Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: Trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening
49. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-humans primates
50. Lipid-lowering therapy in patients with renal disease
51. Impact and management of posttransplant diabetes mellitus
52. Mechanisms of nephrotoxicity
53. The clinical impact of nephrotoxicity in renal transplantation
54. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction
55. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multi-centre study
56. Avoidance of cyclosporine in renal transplantation: Effects of daclizumab, mycophenolate mofetil, and steroids
57. Nonimmunologic renal allograft injury and delayed graft function: Clinical strategies for prevention and treatment